Outcomes of intravenous immunoglobulin treatment of immunocompromised patients with viral respiratory infections

Abstract

BackgroundLimited guidelines exist for treating immunocompromised patients hospitalized for acute viral respiratory infection. Little is known about clinical and economic benefits of intravenous immunoglobulin (IVIG) administration in patients with acute viral respiratory infections. ObjectiveTo compare clinical and economic outcomes among immunocompromised patients hospitalized with viral respiratory infections who received IVIG with those who did not. MethodsWe performed a retrospective cohort study on all patients hospitalized for a respiratory viral infection between 2011 and 2016 at 2 large academic centers including data on age, sex, virus species, immunosuppression type, and receipt of IVIG. Outcomes included death, hospital readmission, length of stay (LOS) in the hospital, and LOS in the intensive care unit (ICU). ResultsA total of 270 patient admissions were reviewed, and 35.6% received IVIG. The average age was 40.6 years, 50% were female, and 74% were transplant patients. The most common virus was rhinovirus (50.7%). Use of IVIG was significantly associated with a shorter ICU LOS (β = −0.534, P = .012) and a longer hospital LOS (β = 0.887, P < .01). IVIG administered within 48 hours of hospitalization (n = 229) was associated with a shorter ICU LOS (β = −2.08, P = .001) and a shorter hospital LOS for patients hospitalized at least 2 days (β = −0.461, P = .007). There were no significant differences in readmission rates or death. ConclusionThis double-center, retrospective cohort analysis is one of the first studies to evaluate the effect of IVIG on immunocompromised patients hospitalized with respiratory viral infections. IVIG was associated with a shorter hospital and ICU LOS, especially when administered within 48 hours of admission.